Centauri Therapeutics secures £30m Series A round for groundbreaking antimicrobial treatments

The threat of drug-resistant bacteria is a growing concern in the field of global health. With limited treatment options available, this notorious issue is leaving patients vulnerable to life-threatening infections. But one biotech company in Cheshire, UK is determined to change that. Centauri Therapeutics, based in Alderley Park, has just secured a whopping £30m in a Series A funding round to support the completion of clinical studies for their revolutionary antimicrobial treatments. This is a major milestone for the company and a significant step forward in the fight against drug-resistant infections.

Centauri Therapeutics: Revolutionizing Antibiotic Treatments

Centauri Therapeutics is a drug discovery company that specializes in developing immunotherapy treatments for infectious diseases. Their groundbreaking approach, using Alphamers, has shown promising results in combatting drug-resistant bacteria. The company's lead clinical candidate, CTX-187, is currently in Phase I clinical studies for the ABX-01 program. This program is specifically focused on targeting Gram-negative bacteria, which are notoriously difficult to treat due to their resistance to traditional antibiotics.

The Series A round of funding, which included a £6m investment from the AMR Action Fund, will support the completion of Phase I clinical studies for CTX-187 and pave the way for further development of this innovative treatment. The AMR Action Fund is a venture capital fund dedicated to supporting companies in the field of antimicrobial therapeutics and diagnostics research. This investment is a testament to the potential of Centauri Therapeutics' approach and the urgent need for new solutions in the fight against drug-resistant infections.

AMR Action Fund CEO, Dr. Henry Skinner, expressed his excitement about the investment, stating, "The growing burden of drug-resistant infections is one of the most pressing challenges in global health. Centauri's approach represents a promising opportunity to address this challenge, and we are pleased to support the team as they advance toward first-in-human studies."

Continued Support from CARB-X

This is not the first major investment Centauri Therapeutics has received for their groundbreaking work. In 2020, they were awarded a £3.8m investment from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This further solidifies the potential of their Alphamer platform and the confidence that investors have in the company's mission to combat drug-resistant infections.

Looking Towards the Future

With the latest investment, Centauri Therapeutics is now well-positioned to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset. This is a significant step forward in bringing their innovative treatments to those who need them most.

CEO of Centauri Therapeutics, Dr. Jennifer Schneider, expressed her enthusiasm for the future, stating, "We are extremely pleased to welcome the AMR Action Fund as a new investor. Their dedication to advancing the field of antimicrobials further reinforces our belief in the Alphamer platform as a transformative immunotherapeutic approach for addressing infections."

In Conclusion

The £30m Series A round secured by Centauri Therapeutics is a testament to the potential of their groundbreaking approach to combating drug-resistant infections. With continued support from investors and organizations like AMR Action Fund and CARB-X, the company is well-equipped to make a significant impact in the field of global health. This is a major step forward in the fight against antimicrobial resistance, and we can't wait to see what the future holds for Centauri Therapeutics.

Source: https://www.uktech.news/news/cheshire-based-biotech-scores-30m-series-a-round-20210615